OKYO Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.11.22	OKYO Pharma Limited – PDMR dealing (GlobeNewswire)
21.11.22	OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease (GlobeNewswire)
10.11.22	OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease (GlobeNewswire)
08.09.22	OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report® (GlobeNewswire)
07.09.22	OKYO Pharma Limited: Result of Annual General Meeting (GlobeNewswire)
30.08.22	OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm (GlobeNewswire)
16.08.22	OKYO Pharma Limited - Final audited results for the year ended 31 March 2022 (GlobeNewswire)
09.06.22	OKYO Pharma Limited - PDMR Dealing (GlobeNewswire)
20.05.22	OKYO Pharma Limited - PDMR Dealing (GlobeNewswire)
19.05.22	OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing (GlobeNewswire)
18.05.22	OKYO Pharma Limited - PDMR Dealing (GlobeNewswire)
17.05.22	OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation (GlobeNewswire)
17.05.22	OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing (GlobeNewswire)
27.04.22	OKYO Pharma ("OKYO" or the "Company") - Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
07.03.22	OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States (GlobeNewswire)
23.02.22	OKYO Pharma ("OKYO" or the "Company") - announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain (GlobeNewswire)
21.02.22	OKYO Pharma Limited ("OKYO" or the "Company") - Conversion of CLNs, cashless exercise of Warrants, and issue of equity (GlobeNewswire)
15.02.22	OKYO Pharma Limited ("OKYO" or the "Company") - OKYO Pharma announces Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease (GlobeNewswire)
01.02.22	OKYO Pharma Limited ("OKYO" or the "Company") - Grant of options – Director and PDMR dealings (GlobeNewswire)
27.01.22	OKYO Pharma Limited- PDMR Dealing (GlobeNewswire)
14.12.21	OKYO Pharma announces issuance of U.S. Patent No. 11,197,906 covering OKYO Pharma’s drug candidate OK-101 for use to treat dry eye disease (GlobeNewswire)
13.12.21	OKYO Pharma Limited ("OKYO" or the "Company") Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease (GlobeNewswire)
06.12.21	OKYO Pharma Limited ("OKYO" or the "Company") to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease ("DED") and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a pl (GlobeNewswire)
01.12.21	OKYO Pharma Limited: Directorate Change (GlobeNewswire)
27.09.21	OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting (GlobeNewswire)
09.09.21	OKYO Pharma Limited ("OKYO" or the "Company") - Notice of Annual General Meeting (GlobeNewswire)
02.08.21	OKYO Pharma Limited Announces final audited results for the year ended 31 March 2021 (GlobeNewswire)
29.06.21	("OKYO" or the "Company") - OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications (GlobeNewswire)
28.04.21	("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain (GlobeNewswire)
29.03.21	OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer (GlobeNewswire)
01.03.21	OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity (GlobeNewswire)
23.02.21	OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation (GlobeNewswire)
19.01.21	OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 a (GlobeNewswire)
25.09.20	OKYO Pharma Limited ("OKYO" or the "Company") - Result of the Annual General Meeting (GlobeNewswire)
09.09.20	Notice of Annual General Meeting (GlobeNewswire)
19.08.20	OKYO Pharma Limited ("OKYO" or the "Company") - Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board (GlobeNewswire)
18.08.20	OKYO Pharma Limited ("OKYO" or the "Company") - Issue of additional convertible loan notes to raise £1,437,104 and intention to seek dual listing on NASDAQ (GlobeNewswire)
07.08.20	Dr James Khodabakhsh MD named Chairman of the Scientific Advisory Board at OKYO Pharma Ltd (GlobeNewswire)
03.08.20	OKYO Pharma Limited ("OKYO" or the "Company") - Company Presentation (GlobeNewswire)
31.07.20	OKYO Pharma Limited - Upcoming Presentation (GlobeNewswire)
28.07.20	OKYO Pharma Limited ("OKYO" or the "Company") - Issue of convertible loan notes to raise £3,500,000 (GlobeNewswire)
28.08.19	OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113, a Novel Agonist of Chemerin G-Protein Coupled Receptor, in a Mouse Model of Dry Eye Disease (Businesswire)
19.08.19	OKYO Pharma Announces Collaboration with Prof. Pedram Hamrah to Evaluate Proprietary Lead Compounds as Non-Opioid Analgesics Targeting G-Protein Coupled Receptors (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novartis	96.30	2.67 %	K V
Logitech Intl	91.54	1.42 %	K V
Part Grp Hldg	1’392.50	1.16 %	K V
Sonova Hldg	321.10	0.75 %	K V
Roche Hldg G	286.80	0.56 %	K V
Zurich Insur Gr	554.60	-0.40 %	K V
ABB	49.88	-0.52 %	K V
Kuehne+Nagel Int	207.70	-0.72 %	K V
Nestle	77.84	-1.07 %	K V
Lonza Grp	583.00	-1.32 %	K V

Nachrichten zu OKYO Pharma Limited Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten